EN PL
PRACA PRZEGLĄDOWA
Rycina z artykułu: Clinical trials in...
 
SŁOWA KLUCZOWE
DZIEDZINY
STRESZCZENIE
Clinical trials are crucial for medical progress, but patient recruitment remains their biggest challenge. The decision to participate stems from a combination of altruistic motivations and the desire to obtain better treatment. The physician plays a key role through their empathy, trustworthiness, and ability to explain the benefits and risks. Problems such as complex protocols, frequent visits, lack of knowledge about the trials, and distrust of pharmaceutical companies significantly hinder recruitment. Patients with chronic pain often hesitate despite severe symptoms, which further complicates the process. It is also important to provide access to study results in the form of understandable plain language summaries, which strengthen patient engagement. Designing “patient-centred” studies can significantly improve their accessibility and effectiveness.
REFERENCJE (38)
1.
Gasparyan AY, Ayvazyan L, Mukanova U, et al. Scientific Hypo­theses: Writing, Promoting, and Predicting Implications. J Korean Med Sci 2019; 34: e300, DOI: 10.3346/jkms.2019.34.e300.
 
2.
Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford) 2012; 51 Suppl 6: vi28–vi36, DOI: 10.1093/rheumatology/kes278.
 
3.
Domańska-Poboża J, Wisłowska M. Evolving strategies in the treatment of rheumatoid arthritis: a historical perspective. Reumatologia 2025; 63: 116–130, DOI: 10.5114/reum/195012.
 
4.
Jeka M, Jeka D, Mojs E. Modern therapies in rheumatology: the role of clinical trials. Rheumatology Forum 2023; 9: 81–87, DOI: 10.5603/RF.a2023.0014.
 
5.
Vulto AG, Jaquez OA. The process defines the product: what really matters in biosimilar design and production? Rheumatology (Oxford) 2017; 56 (Suppl 4): iv14–iv29, DOI: 10.1093/rheumatology/kex278.
 
6.
Kowalik K, Węgierska M, Barczyńska T, Jeka S. Pharmacoeconomic evaluation of costs of rheumatoid arthritis therapy with selected biological treatment. Reumatologia 2018; 56: 340–345, DOI: 10.5114/reum.2018.80710.
 
7.
Obarska I. Nierówności w dostępie do leczenia biologicznego w chorobach autoimmunizacyjnych w Europie. Refundacja apteczna szansą na poprawę efektywności leczenia w Polsce. Polski Związek Pracodawców Przemysłu Farmaceutycznego, Warszawa 2022. Available at: https://ptr.info.pl/raporty/ra... (Access: 09.12.2025).
 
8.
Reed CR, Camargo CA Jr. Recent trends and controversies in industry-sponsored clinical trials. Acad Emerg Med 1999; 6: 833–839, DOI: 10.1111/j.1553-2712.1999.tb01217.x.
 
9.
Chow SC, Chow SS, Pong A. Review of current controversial issues in clinical trials. Gen Psychiatr 2021; 34: e100540, DOI: 10.1136/gpsych-2021-100540.
 
10.
Gouveia R, Cruz VT, Almeida L. Sociodemographic and psychological characteristics influencing patients’ willingness to participate in clinical trials. BMJ Open Qual 2022; 11: e002044, DOI: 10.1136/bmjoq-2022-002044.
 
11.
Jeka M, Jeka D, Daniszewski E, Mojs E. Rheumatic disease patients’ motivations and emotions related to the decision to participate in a clinical trial: preliminary findings. Rheumato­logy Forum 2024; 10: 4–8. DOI: 10.5603/RF.a2023.0017.
 
12.
Clinical Trials: A Study in Moderate to Severe Rheumatoid Arthritis (RA-BEAM). Available at: https://www.clinicaltrials.gov... (Access: 09.12.2025).
 
13.
Clinical Trials: A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis. Available at: https://clinicaltrials.gov/stu... (Access: 09.12.2025).
 
14.
Burmester G, Trefler J, Racewicz A, et al. Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis. Clin Drug Investig 2025; 45: 551–563, DOI: 10.1007/s40261-025-01453-8.
 
15.
Hallowell N, Cooke S, Crawford G, et al. An investigation of patients’ motivations for their participation in genetics-related research. J Med Ethics 2010; 36: 37–45, DOI: 10.1136/jme.2009. 029264.
 
16.
Sun J, Fang J, Zhang C, et al. Acceptance Factors and Psychological Investigation of Clinical Trials in Cancer Patients. Behav Neurol 2023; 2023: 5617575, DOI: 10.1155/2023/5617575.
 
17.
Moorcraft SY, Marriott C, Peckitt C, et al. Patients’ willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey. Trials 2016; 17: 17, DOI: 10.1186/s13063-015-1105-3.
 
18.
Zimba O, Gasparyan AY. Designing, Conducting, and Reporting Survey Studies: A Primer for Researchers. J Korean Med Sci 2023; 38: e403, DOI: 10.3346/jkms.2023.38.e403.
 
19.
Dobra R, Wilson G, Matthews J, et al. A systematic review to identify and collate factors influencing patient journeys through clinical trials. JRSM Open 2023; 14: 20542704231166621, DOI: 10.1177/20542704231166621.
 
20.
Anastasi JK, Capili B, Norton M, et al. Recruitment and retention of clinical trial participants: understanding motivations of patients with chronic pain and other populations. Front Pain Res (Lausanne) 2024; 4: 1330937, DOI: 10.3389/fpain.2023.
 
21.
Ferguson MC, McNicol E, Kleykamp BA, et al. Perspectives on Participation in Clinical Trials Among Individuals With Pain, Depression, and/or Anxiety: An ACTTION Scoping Review. J Pain 2023; 24: 24–37, DOI: 10.1016/j.jpain.2022.09.001.
 
22.
Żuchowski P, Dura M, Kaźmierczak K, et al. Comparison of advanced glycation end products concentration in the skin among patients with rheumatic diseases, with and without comorbid depression: a case-control study. Rheumatol Int 2023; 43: 1829–1834, DOI: 10.1007/s00296-023-05393-4.
 
23.
Waszczak-Jeka M, Żuchowski P, Dura M, et al. Interleukin levels and depressive symptoms in psoriatic arthritis patients: insights from a case-control study on socio-demographic factors and disease perception. Rheumatol Int 2024; 44: 1337–1343, DOI: 10.1007/s00296-024-05599-0.
 
24.
De Lorenzis E, Natalello G, Bruno D, et al. Psoriatic arthritis and depressive symptoms: does systemic inflammation play a role? Clin Rheumatol 2021; 40: 1893–1902, DOI: 10.1007/s10067-020-05417-5.
 
25.
Bloostein A, Caricchio R. Patient-Reported Factors Influencing Clinical Trial Participation: An In-depth Analysis of Patients With Lupus and Rheumatoid Arthritis. ACR Open Rheumatol 2025; 7: e70035, DOI: 10.1002/acr2.70035.
 
26.
Kerschbaumer A, Steiner M, Pruckner P, et al. Global recruitment patterns and placebo responses in clinical trials of rheumatoid arthritis. Ann Rheum Dis 2025; 84: 1632–1640, DOI: 10.1016/j.ard.2025.07.010.
 
27.
Dean A, Rose F, Jones K, et al. Why do people take part in vaccine trials? A mixed methods narrative synthesis. Patient Educ Couns 2023; 114: 107861, DOI: 10.1016/j.pec.2023.107861.
 
28.
Patel PV, Purvis CG, Hamid RN, Feldman SR. Biosimilars in dermatology: identifying myths and knowledge gaps. Dermatol Online J 2023; 29, DOI: 10.5070/D329361423.
 
29.
Cheung YK, Wood D, Zhang K, et al. Personal preferences for Personalised Trials among patients with chronic diseases: an empirical Bayesian analysis of a conjoint survey. BMJ Open 2020; 10: e036056, DOI: 10.1136/bmjopen-2019-036056.
 
30.
Smith SM, Gewandter JS, Kitt RA, et al. Participant Preferences for Pharmacologic Chronic Pain Treatment Trial Characteristics: An ACTTION Adaptive Choice-Based Conjoint Study. J Pain 2016; 17: 1198–1206, DOI: 10.1016/j.jpain.2016.07.008.
 
31.
Nguyen VT, Ravaud P, Tran VT, et al. Patients’ Perspectives on Transforming Clinical Trial Participation: Large Online Vignette- based Survey. J Med Internet Res 2022; 24: e29691, DOI: 10.2196/29691.
 
32.
https://www.wma.net/policies-p...- helsinki/ [date of entry: 06/JAN/2026].
 
33.
Kujawa K, Bombała W, Kopszak A, et al. New statistical guidelines for manuscripts submitted to Advances in Clinical and Experimental Medicine. Adv Clin Exp Med 2025; 34: 1085–1090, DOI: 10.17219/acem/206009.
 
34.
Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520–1528, DOI: 10.1056/NEJM200011233432103.
 
35.
Waxman HA. The lessons of Vioxx – drug safety and sales. N Engl J Med 2005; 352: 2576–2578, DOI: 10.1056/NEJMp058136.
 
36.
Gudi SK, Tiwari KK, Panjwani K. Plain-language summaries: An essential component to promote knowledge translation. Int J Clin Pract 2021; 75: e14140, DOI: 10.1111/ijcp.14140.
 
37.
Jeka S, Dokoupilová E, Kivitz A, et al. Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study. J Bone Miner Res 2024; 39: 202–210, DOI: 10.1093/jbmr/zjae016.
 
38.
Eastell R, Jeka S, Lustberg M, et al. Plain language summary of publication to understand the ROSALIA study: a new biosimilar denosumab for bone health. Ther Adv Musculoskelet Dis 2025; 17: 1759720X251335147, DOI: 10.1177/ 1759720X251335147.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top